



NEWS RELEASE

MDxHealth Expands Its Companion Diagnostics Capabilities

DURHAM, NC, and LIEGE, BELGIUM – December 21, 2010 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has expanded its presence and capabilities in the growing field of companion diagnostics with the establishment of a new division in Ghent, Belgium, MDxHealth PharmacoDx bvba.

The opening of the new MDxHealth PharmacoDx facility in the Technology Park of Ghent builds upon the Company's long-standing collaboration with Ghent University in the area of bio-informatics and translational medicine. MDxHealth intends to leverage next generation epigenetic sequencing technology in collaboration with Ghent University to enhance its offering and design of companion diagnostic and other tests for optimized drug development and the treatment of cancer. MDxHealth will integrate its existing Flemish subsidiary and personnel with the new MDxHealth PharmacoDx facility.

"Strengthening our collaboration with Ghent University is key for our pharmaco-diagnostic development capabilities. The development and commercialization of clinical and companion diagnostics are at the heart of MDxHealth's growth strategy," said Dr. Jan Groen, Chief Executive Officer of MDxHealth.

Based on its industry-leading methylation technology, MDxHealth already possesses an extensive pipeline of companion diagnostics. Its patented technology and patented biomarkers are being used for numerous cancer applications and therapies in development. Pharmaceutical companies like Merck Serono, Abbott, Roche, GlaxoSmithKline Biologicals, and others have projects currently in place with MDxHealth.

About MDxHealth

MDxHealth is a leading molecular diagnostics company that develops and commercializes oncology-based molecular diagnostic testing and companion diagnostics for personalized medicine. The company's numerous cancer tests are based on proprietary gene methylation technology and are designed to assist physicians in the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth collaborates with leading cancer research centers such as Johns Hopkins University, Duke University, Lovelace Respiratory Research Institute, Eastern Virginia Medical School, Cleveland Clinic, Memorial Sloan Kettering, and major European academic medical centers. The company has a number of commercial and collaborative partnerships with LabCorp, Merck & Co./Schering Plough, GlaxoSmithKline Biologicals, Roche, Merck Serono, Qiagen, and other industry leaders.

MDxHealth to present at Biotech Showcase in San Francisco on January 10, 2011

MDxHealth will present at the Biotech Showcase Conference in San Francisco, on Monday, Jan. 10, 2011. Dr. Jan Groen, chief executive officer, will make a formal presentation on the company at 2 p.m. Pacific time. The Biotech Showcase runs parallel to the 28th Annual J.P. Morgan Healthcare Conference, and takes place at Parc 55 Wyndham San Francisco - Union Square.

For more information:

Dr. Jan Groen, CEO
MDxHealth
+32 4 364 20 70

Hans Herklots
Capricorn One
+41 79 598 7149

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation